Neurocrine Biosciences to Address Neurological Advances at Stifel Virtual CNS Forum
Neurocrine Biosciences to Present at Stifel 2025 Virtual CNS Forum
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is set to make a significant appearance at the Stifel 2025 Virtual CNS Forum on March 18, 2025, at 1:30 PM Eastern Time. This anticipated event will showcase key insights from the company’s leadership, including CEO Kyle Gano and CMO Eiry Roberts, who will present updates on their latest advancements in neuroscience.
The conference aims to connect investors, researchers, and industry professionals with groundbreaking developments that Neurocrine is championing in the realm of neuroscience. Attendees can look forward to gaining comprehensive insights into the biotechnology firm’s ongoing projects and future directions into the treatment of neurological disorders.
For those interested, the live event will be accessible via a webcast available on Neurocrine Biosciences' official website under the 'Investors' section. Furthermore, a replay will be provided approximately one hour after the event, remaining accessible for about a month for individuals unable to attend live.
About Neurocrine Biosciences
Neurocrine Biosciences, founded three decades ago, is a leading biopharmaceutical company focused specifically on neuroscience. The organization harbors a steadfast commitment to alleviating the suffering faced by patients with significant, unmet medical needs. Their efforts are concentrated on discovering and developing innovative treatments that target neurological, neuroendocrine, and neuropsychiatric disorders.
Among its successful portfolio, Neurocrine has achieved FDA approval for various treatments that address conditions like tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids, the latter two being in collaboration with AbbVie. The company is not just resting on its laurels; it possesses a robust pipeline filled with multiple compounds currently undergoing mid- to late-stage clinical evaluations.
With a deep understanding of the intricate connections between brain functions and bodily systems, Neurocrine strives to tackle complex neurological conditions by leveraging decades of research and innovative science. Their dedication to healthcare is encapsulated in their motto, “You deserve brave science,” reflecting their ongoing pursuit of revolutionary treatments that can significantly improve the quality of life for patients.
As the Stifel 2025 Virtual CNS Forum approaches, stakeholders eager for insight into Neurocrine’s advancements in neuroscience should mark their calendars for March 18. This event not only represents an opportunity for investors, but also for anyone invested in the future of neurological wellness.
To learn more about Neurocrine Biosciences, visit their website at neurocrine.com and follow them on LinkedIn, X (formerly Twitter), and Facebook.
In summary, the upcoming forum heralds an exciting chapter for Neurocrine Biosciences as they continue to pioneer advancements in largely underserved areas of medicine, polarizing their vision of a world free from the burdens of debilitating neurological disorders.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.